Annovis Bio (ANVS) Competitors $2.32 0.00 (0.00%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$2.32 0.00 (0.00%) As of 08/29/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, TNYA, TIL, SXTC, DERM, IMRX, NVCT, ACTU, CRBU, and TVGNShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Tenaya Therapeutics (TNYA), Instil Bio (TIL), China SXT Pharmaceuticals (SXTC), Journey Medical (DERM), Immuneering (IMRX), Nuvectis Pharma (NVCT), Actuate Therapeutics (ACTU), Caribou Biosciences (CRBU), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Tenaya Therapeutics Instil Bio China SXT Pharmaceuticals Journey Medical Immuneering Nuvectis Pharma Actuate Therapeutics Caribou Biosciences Tevogen Bio ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership. Does the media refer more to ALXO or ANVS? In the previous week, ALX Oncology had 2 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for ALX Oncology and 1 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.77 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ALXO or ANVS? ALX Oncology has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Which has higher valuation and earnings, ALXO or ANVS? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.53Annovis BioN/AN/A-$24.59M-$2.04-1.14 Do institutionals & insiders have more ownership in ALXO or ANVS? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ALXO or ANVS more profitable? ALX Oncology's return on equity of -115.67% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Annovis Bio N/A -206.01%-158.26% Do analysts recommend ALXO or ANVS? ALX Oncology presently has a consensus target price of $3.30, indicating a potential upside of 182.05%. Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 675.86%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryALX Oncology beats Annovis Bio on 9 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$45.21M$3.06B$5.68B$21.35BDividend YieldN/A2.29%3.99%3.50%P/E Ratio-1.1420.9283.1129.31Price / SalesN/A386.08533.3952.35Price / CashN/A44.0537.7024.03Price / Book2.478.0710.575.36Net Income-$24.59M-$53.98M$3.27B$996.52M7 Day Performance-2.60%-0.86%0.57%0.37%1 Month Performance-16.25%6.22%5.99%4.73%1 Year Performance-72.64%7.17%48.91%11.72% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio1.9283 of 5 stars$2.32flat$18.00+675.9%-73.7%$45.21MN/A-1.143ALXOALX Oncology3.1108 of 5 stars$1.10-6.0%$3.30+200.0%-49.1%$62.65MN/A-0.5040TNYATenaya Therapeutics2.8382 of 5 stars$1.07-5.3%$6.25+484.1%-59.2%$184.16MN/A-1.11110News CoverageAnalyst ForecastGap UpTILInstil Bio3.5503 of 5 stars$25.71-4.7%$119.00+362.9%+115.2%$182.20MN/A-1.99410Analyst ForecastSXTCChina SXT Pharmaceuticals0.4074 of 5 stars$1.48-5.7%N/A-73.6%$182.16M$1.74M0.0090Gap UpDERMJourney Medical1.6872 of 5 stars$7.40-0.9%$12.17+64.4%+38.4%$182.10M$56.13M-19.4790Analyst RevisionIMRXImmuneering3.4717 of 5 stars$5.95+21.7%$13.25+122.7%+395.7%$177.60M$320K-3.1560Analyst ForecastHigh Trading VolumeNVCTNuvectis Pharma3.4533 of 5 stars$6.49-5.5%$15.33+136.3%-3.4%$174.89MN/A-5.558ACTUActuate TherapeuticsN/A$7.98-4.5%$20.50+156.9%+3.8%$173.43MN/A0.0010Trending NewsAnalyst ForecastAnalyst RevisionCRBUCaribou Biosciences2.7674 of 5 stars$1.88+1.6%$6.67+254.6%-11.4%$172.28M$9.99M-1.06100TVGNTevogen Bio3.7848 of 5 stars$0.92-1.8%$10.00+987.0%+82.8%$172.20MN/A0.003 Related Companies and Tools Related Companies ALX Oncology Competitors Tenaya Therapeutics Competitors Instil Bio Competitors China SXT Pharmaceuticals Competitors Journey Medical Competitors Immuneering Competitors Nuvectis Pharma Competitors Actuate Therapeutics Competitors Caribou Biosciences Competitors Tevogen Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts